| Size | Price | |
|---|---|---|
| 500mg | ||
| Other Sizes |
| Targets |
m-PEG7-amine targets primary amine-reactive functional groups. The terminal amine reacts with carboxylic acids, NHS esters, isocyanates, and carbonyls to form stable amide or urea bonds. In ADCs and PROTACs, it serves as a linker component. The PEG7 spacer provides hydrophilicity and flexibility.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
As a chemical linker, m-PEG7-amine has no intrinsic pharmacological activity. Its utility is defined by its terminal amine reactivity. The PEG7 spacer provides excellent water solubility and reduces aggregation. The compound has a density of 1.046 g/cm³ and is soluble in DCM, DMF, and DMSO. |
| ln Vivo |
No direct in vivo activity is attributed to m-PEG7-amine. It functions as a linker in ADCs and PROTACs. The amine group enables conjugation to payload molecules. The PEG7 spacer improves solubility and reduces immunogenicity of the final conjugate.
|
| Enzyme Assay |
For non-cell-based assays, m-PEG7-amine is characterized by NMR and HPLC (≥98% purity). The amine content can be quantified by titration or derivatization. Reactivity can be tested by reacting with a model NHS ester and monitoring by HPLC or LC-MS.
|
| Cell Assay |
Cell-based assays are not performed on m-PEG7-amine alone. It is used to synthesize ADCs or PROTACs, which are then evaluated in cell culture. Standard protocols involve treating cancer cell lines with the conjugate at 0.001-10 µM for 24-72 hours.
|
| Animal Protocol |
In vivo studies with m-PEG7-amine are conducted using the final ADC or PROTAC construct. Typical protocols involve administering the conjugate to tumor-bearing mouse models via intravenous injection at 1-10 mg/kg. The PEG7 spacer contributes to prolonged circulation and enhanced efficacy.
|
| ADME/Pharmacokinetics |
As a linker, m-PEG7-amine does not have independent PK properties. The PEG7 spacer improves aqueous solubility and reduces clearance. The compound has a molecular weight of 339.43 and a density of 1.046 g/cm³. Storage at 4°C, protected from light, is recommended.
|
| Toxicity/Toxicokinetics |
Toxicology data specific to m-PEG7-amine are limited. The amine group may be irritating; standard safety precautions apply. PEG derivatives are biocompatible. No significant acute toxicity is expected.
|
| References |
[1]. Iain Mcculloch, et al. N-type conjugated polymers. WO2018211286A1.
|
| Additional Infomation |
m-PEG7-amine is a cleavable ADC linker and a PEG-based PROTAC linker. Synonyms include 2,5,8,11,14,17,20-heptaoxadocosan-22-amine. The primary amine functionality enables efficient coupling to activated carboxylic acids and NHS esters. No clinical trials exist.
|
| Molecular Formula |
C15H33NO7
|
|---|---|
| Molecular Weight |
339.42502
|
| Exact Mass |
339.226
|
| CAS # |
170572-38-0
|
| PubChem CID |
18764651
|
| Appearance |
Colorless to light yellow liquid（Density：1.046 g/cm3）
|
| Density |
1.046
|
| LogP |
0.391
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
20
|
| Heavy Atom Count |
23
|
| Complexity |
210
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COCCOCCOCCOCCOCCOCCOCCN
|
| InChi Key |
IQQSLHPGFFGOJW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H33NO7/c1-17-4-5-19-8-9-21-12-13-23-15-14-22-11-10-20-7-6-18-3-2-16/h2-16H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~294.6 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9461 mL | 14.7306 mL | 29.4612 mL | |
| 5 mM | 0.5892 mL | 2.9461 mL | 5.8922 mL | |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9461 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
